According to Zacks, “Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. “
Shares of Aeglea Biotherapeutics (NASDAQ:AGLE) opened at 6.75 on Tuesday. The firm has a 50 day moving average price of $6.76 and a 200-day moving average price of $6.60. The company’s market cap is $90.52 million. Aeglea Biotherapeutics has a 52-week low of $3.89 and a 52-week high of $12.75.
Aeglea Biotherapeutics (NASDAQ:AGLE) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.03. Equities research analysts anticipate that Aeglea Biotherapeutics will post ($4.77) earnings per share for the current year.
Institutional investors have recently bought and sold shares of the company. VHCP Management II LLC bought a new position in Aeglea Biotherapeutics during the second quarter worth approximately $1,527,000. Ghost Tree Capital LLC acquired a new stake in shares of Aeglea Biotherapeutics during the second quarter worth about $243,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Aeglea Biotherapeutics during the second quarter worth about $515,000. 40.71% of the stock is owned by hedge funds and other institutional investors.
Aeglea Biotherapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.